Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anlon HealthcareNSE:AHCL +1.99%19 3-Year EBITDA Growth Rate is 60.40% as of Jun. 2026, which is 12% below its 10-year median of 68.40. GuruFocus rates NSE:AHCL with a GF Score™ of 19/100. The stock has 5 warning signs investors should review. Among 809 Drug Manufacturers companies, Anlon Healthcare ranks better than 90.98% on this metric.
During the past 12 months, Anlon Healthcare's average EBITDA Per Share Growth Rate was 5443.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 60.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Anlon Healthcare was 76.40% per year. The lowest was 60.40% per year. And the median was 68.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Anlon Healthcare 3-Year EBITDA Growth Rate Related Terms
NSE:AHCL vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Anlon Healthcare's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anlon Healthcare 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anlon Healthcare's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Anlon Healthcare's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 60.40% mean?
Anlon Healthcare (NSE:AHCL) has a 3-Year EBITDA Growth Rate of 60.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Anlon Healthcare and its competitors. This is 12% below median its historical median of 68.40. Over the past decade, Anlon Healthcare's 3-Year EBITDA Growth Rate has ranged from 60.40 to 76.40. According to the industry distribution chart, Anlon Healthcare ranks #73 out of 809 companies in the Drug Manufacturers industry, placing it in the top 9%.
Is Anlon Healthcare's 3-Year EBITDA Growth Rate too high?
Anlon Healthcare's current 3-Year EBITDA Growth Rate of 60.40% is 12% below median its 10-year median of 68.40. Over the past 10 years, this metric has ranged from a low of 60.40 to a high of 76.40. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Anlon Healthcare's value of 60.40% is 578.7% above this industry median. Based on the distribution chart, Anlon Healthcare ranks #73 out of 809 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Anlon Healthcare has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Anlon Healthcare's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Anlon Healthcare ranks #73 out of 809 companies for 3-Year EBITDA Growth Rate. This places Anlon Healthcare in the top 9% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Anlon Healthcare's value of 60.40% is 578.7% above this benchmark. Historically, Anlon Healthcare's own 3-Year EBITDA Growth Rate has ranged from 60.40 to 76.40 over the past decade. While the company's 10-year median is 68.40 vs. the industry median of 8.90, Anlon Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anlon Healthcare's current 3-Year EBITDA Growth Rate of 60.40% is 578.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Anlon Healthcare and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anlon Healthcare's current 3-Year EBITDA Growth Rate is 60.40%, which is 12% below median its own 10-year median of 68.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anlon Healthcare stock overvalued right now?
Anlon Healthcare (NSE:AHCL) has a current 3-Year EBITDA Growth Rate of 60.40%. The current 3-Year EBITDA Growth Rate is 60.40%, which is 12% below median its 10-year median of 68.40 and 578.7% above the Drug Manufacturers industry median of 8.90. Anlon Healthcare's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Anlon Healthcare (NSE:AHCL), the current 3-Year EBITDA Growth Rate is 60.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anlon Healthcare Ltd is a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products. Its products spans across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API.
19GF Score
Get the complete analysis for NSE:AHCL
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AHCL has been successfully added to your 
